B

Bergenbio ASA
OSE:BGBIO

Watchlist Manager
Bergenbio ASA
OSE:BGBIO
Watchlist
Price: 9.068 NOK 3.43%
Market Cap: 354.5m NOK
Have any thoughts about
Bergenbio ASA?
Write Note

P/OCF
Price to OCF

-2.5
Current
-167.2
Median
21.6
Industry
Higher than median
Lower than industry value

Price to Operating Cash Flow (P/OCF) ratio is a valuation multiple that measures the value of a company’s market capitalization relative to the operating cash flow it generates. Some analysts prefer P/OCF over P/E since earnings can be more easily manipulated than cash flows.

P/OCF
-2.5
=
Market Cap
342.7m NOK
/
Operating Cash Flow
-139m NOK
All Countries
Close
Market Cap P/OCF
NO
Bergenbio ASA
OSE:BGBIO
342.7m NOK -2.5
FR
Pharnext SCA
OTC:PNEXF
6T USD -241 760.2
US
Abbvie Inc
NYSE:ABBV
315.4B USD 19.1
US
Amgen Inc
NASDAQ:AMGN
142B USD 19.6
US
Gilead Sciences Inc
NASDAQ:GILD
111.1B USD 11.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
106.2B USD -126.1
US
Epizyme Inc
F:EPE
94.1B EUR -465.3
AU
CSL Ltd
ASX:CSL
139B AUD 31.3
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
80.8B USD 19
US
Seagen Inc
F:SGT
39.3B EUR -75.1
NL
argenx SE
XBRU:ARGX
38.2B EUR -151.7
 
NO
B
Bergenbio ASA
OSE:BGBIO
Average P/OCF: 20
Negative Multiple: -2.5
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -241 760.2
US
Abbvie Inc
NYSE:ABBV
19.1
US
Amgen Inc
NASDAQ:AMGN
19.6
US
Gilead Sciences Inc
NASDAQ:GILD
11.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -126.1
US
E
Epizyme Inc
F:EPE
Negative Multiple: -465.3
AU
CSL Ltd
ASX:CSL
31.3
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
19
US
S
Seagen Inc
F:SGT
Negative Multiple: -75.1
NL
argenx SE
XBRU:ARGX
Negative Multiple: -151.7

P/OCF Forward Multiples

Forward P/OCF multiple is a version of the P/OCF ratio that uses forecasted operating cash flow for the P/OCF calculation. 1-Year, 2-Years, and 3-Years forwards use operating cash flow forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
P/OCF
N/A
2-Years Forward
P/OCF
N/A
3-Years Forward
P/OCF
N/A